Metabolic Comorbidity in Preclinical Stroke, Pain and Wound Models
Among US adults aged 60 and older, metabolic syndrome prevalence reached roughly 62 percent by 2021 to 2023 in a national survey analysis published...
Among US adults aged 60 and older, metabolic syndrome prevalence reached roughly 62 percent by 2021 to 2023 in a national survey analysis published...
The pain and neurology pipeline comprises several distinct therapeutic modalities. A neuropathic pain program today may be a small molecule sodium...
Remyelination trials in multiple sclerosis are judged on imaging and functional endpoints because myelin cannot be examined directly in a patient. A...
Pain is a principal presenting symptom of rheumatoid arthritis, and persistent pain despite low inflammatory activity is now the subject of its own...
The clinical value of a non-opioid analgesic is defined relative to the established agents it is intended to replace, so its preclinical evaluation...
Multiple sclerosis therapy has been transformed by agents that control inflammation, and the unmet need has shifted toward repair. Remyelination has...
The FDA issued draft guidance on the development of non-opioid analgesics for acute pain in 2022, covering development programs, labeling claims and...
The GLP-1 receptor agonists have changed the trajectory of type 2 diabetes care, and the evidence now suggests their reach extends to the diabetic...
Postoperative pain management is in the middle of a reimbursement shift. Since January 2025, Medicare has paid separately for qualifying non-opioid...